Form 4: Oric Pharmaceuticals Director Dier Mardi Acquires Stock Options
SEC Form 4 Filing
Director Dier Mardi acquired 25,600 stock options in Oric Pharmaceuticals on June 12, 2024.
Summary
- On June 12, 2024, Dier Mardi, a director of Oric Pharmaceuticals, acquired 25,600 stock options.
- The exercise price of these options is $7.90.
- The options vest on the earlier of June 12, 2025, or the business day before the next annual meeting of the Issuer's stockholders following the grant date.
- The options expire on June 11, 2034.
- Following the transaction, Dier Mardi directly owns 25,600 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.
Stakeholder Impact
- Shareholders may view insider transactions as a signal of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of the stock option transaction. |
| 06/12/2025 | First possible vesting date for the stock options. |
| 06/11/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.